The FDA Desk — 2026-04-25

TITLE: The FDA Desk — 2026-04-25: Fresenius Kabi saline sweep, Fagron vancomycin, Teva clonidine patches

---

Today's Docket

No Class I recalls posted. All ten entries are Class II, firm-initiated, and concentrate around three manufacturers and three distinct root causes. Nothing here requires immediate patient notification for risk of death or serious injury, but sterility and CGMP themes suggest ongoing facility-level compliance issues worth monitoring.

Sterility Failures — Fresenius Kabi Saline Line

Fresenius Kabi USA, LLC (Lake Zurich, IL) initiated a broad recall on 2026-03-11 across its freeflex bag saline portfolio, in every case citing "Lack of Assurance of Sterility." The scope spans multiple concentrations, volumes, and distribution channels (including product distributed under the BD label), pointing to a process- or facility-level sterility assurance finding rather than a single lot defect.

• D-0427-2026, D-0426-2026, D-0432-2026, and D-0428-2026 cover 0.9% Sodium Chloride Injection USP in 100 mL, 250 mL, and 500 mL freeflex bag presentations distributed directly by Fresenius Kabi.
• D-0430-2026 extends the same sterility issue to 0.9% Sodium Chloride 100 mL bags manufactured by Fresenius Kabi but distributed by BD (Becton, Dickinson and Company), Franklin Lakes, NJ — expanding the downstream hospital-inventory footprint.
• D-0424-2026 applies the same finding to 0.45% Sodium Chloride Injection USP, 250 mL freeflex (NDC 63323-626-03), indicating the issue is not confined to isotonic saline.

Purchasers should expect Fresenius Kabi customer notifications tracing back to the same March 11 action; hospitals and compounders relying on freeflex saline as a diluent should audit on-hand stock against the affected NDCs.

Compounded Vancomycin — Fagron Sterile Services

Fagron Sterile Services (Wichita, KS) initiated two Class II recalls on 2026-03-20 of compounded Vancomycin HCl in 0.9% Sodium Chloride Injection USP, flagging both a sterility assurance gap *and* a device defect in which the blue Break-Off-Part could detach from the administration port — a dual-mode failure with potential for particulate contamination and dosing disruption.

• D-0441-2026 covers the 1.5 g / 250 mL presentation (NDC 71266-5085-01).
• D-0440-2026 covers the 1.25 g / 250 mL presentation (NDC 71266-5083-01).

Given that these are compounded antibiotics typically administered to inpatients with serious infections, infusion teams should physically inspect administration ports before use on any unrecalled inventory from this facility.

CGMP Deviation — Teva Clonidine Transdermal Systems

Teva Pharmaceuticals USA, Inc., acting through Actavis Laboratories UT Inc. (Salt Lake City) and Actavis Pharma (Parsippany, NJ), initiated Class II recalls on 2026-03-19 of Clonidine Transdermal System USP for CGMP Deviations: use of an unapproved raw material. This is a manufacturing-integrity finding rather than a finished-product performance complaint, but it affects both marketed strengths:

• D-0472-2026 — Clonidine Transdermal System 0.1 mg/day, cartons of 4 systems plus 4 adhesive covers.
• D-0473-2026 — Clonidine Transdermal System 0.2 mg/day, same carton configuration.

Pharmacists dispensing chronic hypertension or off-label ADHD patients on these patches should coordinate substitution plans; the unapproved-raw-material basis means the affected lots are unlikely to be reworked and returned to market.

Editor's Note

Three themes, three manufacturers, one shared week in mid-to-late March for root-cause dates — all surfacing on today's FDA Enforcement Report. The Fresenius Kabi cluster is the highest-volume exposure by unit count given saline's ubiquity as a diluent; the Fagron and Teva actions are narrower but clinically more specific. Watch for whether Fresenius Kabi's sterility finding expands to additional product families in subsequent weekly reports.